Zharkov Dmitry O, Yudkina Anna V, Riesebeck Tim, Loshchenova Polina S, Mostovich Evgeny A, Dianov Grigory L
Novosibirsk State University 2 Pirogova Street, Novosibirsk 630090, Russia.
SB RAS Institute of Chemical Biology and Fundamental Medicine 8 Lavrentieva Avenue, Novosibirsk 630090, Russia.
Am J Cancer Res. 2021 Oct 15;11(10):4668-4682. eCollection 2021.
Despite the significant progress in cancer cure, the development of new approaches to cancer therapy is still of great importance since many deadly tumors remain untreatable. Boron neutron capture therapy (BNCT), proposed more than eighty years ago, is still considered a potentially advantageous approach. Irradiation of cells containing B isotopes with epithermal neutrons and the consequent decay of boron nuclei releases particles that deposit high energy along a very short path, inflicting heavy damage on the target cells but sparing the neighbouring tissue. Delivery and preferential accumulation of boron in cancer cells are the major obstacles that slow down the clinical use of BNCT. Since DNA damage caused by irradiation is the major reason for cell death, the incorporation of boron-containing nucleotides into the DNA of cancer cells may significantly increase the efficacy of BNCT. In this review, we discuss the current state of knowledge in the synthesis of boron-containing nucleosides and their application for BNCT with a special focus on their possible incorporation into genomic DNA.
尽管在癌症治疗方面取得了重大进展,但开发新的癌症治疗方法仍然非常重要,因为许多致命肿瘤仍然无法治疗。八十多年前提出的硼中子俘获疗法(BNCT)仍然被认为是一种潜在的优势方法。用超热中子辐照含有硼同位素的细胞,随后硼核的衰变会释放出沿极短路径沉积高能量的粒子,对靶细胞造成严重损伤,同时使邻近组织免受损伤。硼在癌细胞中的递送和优先积累是阻碍BNCT临床应用的主要障碍。由于辐射引起的DNA损伤是细胞死亡的主要原因,将含硼核苷酸掺入癌细胞的DNA中可能会显著提高BNCT的疗效。在这篇综述中,我们讨论了含硼核苷合成的当前知识状态及其在BNCT中的应用,特别关注它们可能掺入基因组DNA的情况。